Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Sell
44
LXRX Quote, Financials, Valuation and Earnings
Last price:
$1.32
Seasonality move
:
-9.17%
Day range:
$1.28 - $1.35
52-week range:
$0.28 - $1.83
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.70x
P/B ratio:
3.96x
Volume:
1.1M
Avg. volume:
3.2M
1-year change:
76.72%
Market cap:
$476.1M
Revenue:
$31.1M
EPS (TTM):
-$0.19
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LXRX
Lexicon Pharmaceuticals, Inc.
|
$5.8M | -$0.07 | 347.7% | -7.01% | $2.92 |
|
AGEN
Agenus, Inc.
|
$28.2M | -$0.40 | 329.24% | -36.28% | $12.33 |
|
CRIS
Curis, Inc.
|
$3.2M | -$0.31 | -2.86% | -65.51% | $14.00 |
|
LADX
LadRx Corp.
|
-- | -- | -- | -- | -- |
|
NVAX
Novavax, Inc.
|
$107.7M | -$0.12 | -84.58% | -9.36% | $12.89 |
|
VMD
Viemed Healthcare, Inc.
|
$81.9M | $0.10 | 30.82% | 25% | $13.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LXRX
Lexicon Pharmaceuticals, Inc.
|
$1.31 | $2.92 | $476.1M | -- | $0.00 | 0% | 6.70x |
|
AGEN
Agenus, Inc.
|
$2.92 | $12.33 | $105.5M | -- | $0.00 | 0% | 0.74x |
|
CRIS
Curis, Inc.
|
$1.15 | $14.00 | $14.9M | -- | $0.00 | 0% | 1.10x |
|
LADX
LadRx Corp.
|
$0.10 | -- | $51.2K | 0.84x | $0.00 | 0% | -- |
|
NVAX
Novavax, Inc.
|
$8.70 | $12.89 | $1.4B | 4.92x | $0.00 | 0% | 1.38x |
|
VMD
Viemed Healthcare, Inc.
|
$8.28 | $13.00 | $314.8M | 25.05x | $0.00 | 0% | 1.34x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LXRX
Lexicon Pharmaceuticals, Inc.
|
35.09% | 3.231 | 13.24% | 5.45x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.019 | 285.06% | 0.03x |
|
CRIS
Curis, Inc.
|
192.35% | 2.868 | 144.76% | 0.62x |
|
LADX
LadRx Corp.
|
-- | 2.863 | -- | -- |
|
NVAX
Novavax, Inc.
|
265.85% | 2.162 | 17.83% | 1.90x |
|
VMD
Viemed Healthcare, Inc.
|
15.6% | 0.146 | 9.5% | 0.87x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LXRX
Lexicon Pharmaceuticals, Inc.
|
$14M | -$12.2M | -30.03% | -49.19% | -85.93% | -$23.8M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
CRIS
Curis, Inc.
|
$3.1M | -$6.9M | -147.67% | -461.34% | -218.01% | -$5.6M |
|
LADX
LadRx Corp.
|
-- | -$719.8K | -- | -- | -- | -$552.8K |
|
NVAX
Novavax, Inc.
|
$50.6M | -$79.4M | -- | -- | -112.72% | $105.8M |
|
VMD
Viemed Healthcare, Inc.
|
$40.9M | $7M | 9.63% | 10.37% | 9.69% | $10.7M |
Lexicon Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns LXRX or AGEN?
Agenus, Inc. has a net margin of -90.04% compared to Lexicon Pharmaceuticals, Inc.'s net margin of -116.82%. Lexicon Pharmaceuticals, Inc.'s return on equity of -49.19% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LXRXLexicon Pharmaceuticals, Inc.98.87% -$0.04 $185.1M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About LXRX or AGEN?
Lexicon Pharmaceuticals, Inc. has a consensus price target of $2.92, signalling upside risk potential of 122.9%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 322.37%. Given that Agenus, Inc. has higher upside potential than Lexicon Pharmaceuticals, Inc., analysts believe Agenus, Inc. is more attractive than Lexicon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LXRXLexicon Pharmaceuticals, Inc.2 2 0 AGENAgenus, Inc.2 1 0 -
Is LXRX or AGEN More Risky?
Lexicon Pharmaceuticals, Inc. has a beta of 0.980, which suggesting that the stock is 1.993% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.86%.
-
Which is a Better Dividend Stock LXRX or AGEN?
Lexicon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LXRX or AGEN?
Lexicon Pharmaceuticals, Inc. quarterly revenues are $14.2M, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Lexicon Pharmaceuticals, Inc.'s net income of -$12.8M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Lexicon Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals, Inc. is 6.70x versus 0.74x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LXRXLexicon Pharmaceuticals, Inc.6.70x -- $14.2M -$12.8M AGENAgenus, Inc.0.74x -- $30.2M $63.9M
-
Which has Higher Returns LXRX or CRIS?
Curis, Inc. has a net margin of -90.04% compared to Lexicon Pharmaceuticals, Inc.'s net margin of -243.36%. Lexicon Pharmaceuticals, Inc.'s return on equity of -49.19% beat Curis, Inc.'s return on equity of -461.34%.
Company Gross Margin Earnings Per Share Invested Capital LXRXLexicon Pharmaceuticals, Inc.98.87% -$0.04 $185.1M CRISCuris, Inc.98.52% -$0.49 $15.9M -
What do Analysts Say About LXRX or CRIS?
Lexicon Pharmaceuticals, Inc. has a consensus price target of $2.92, signalling upside risk potential of 122.9%. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 1117.39%. Given that Curis, Inc. has higher upside potential than Lexicon Pharmaceuticals, Inc., analysts believe Curis, Inc. is more attractive than Lexicon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LXRXLexicon Pharmaceuticals, Inc.2 2 0 CRISCuris, Inc.4 0 0 -
Is LXRX or CRIS More Risky?
Lexicon Pharmaceuticals, Inc. has a beta of 0.980, which suggesting that the stock is 1.993% less volatile than S&P 500. In comparison Curis, Inc. has a beta of 3.078, suggesting its more volatile than the S&P 500 by 207.818%.
-
Which is a Better Dividend Stock LXRX or CRIS?
Lexicon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LXRX or CRIS?
Lexicon Pharmaceuticals, Inc. quarterly revenues are $14.2M, which are larger than Curis, Inc. quarterly revenues of $3.2M. Lexicon Pharmaceuticals, Inc.'s net income of -$12.8M is lower than Curis, Inc.'s net income of -$7.7M. Notably, Lexicon Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals, Inc. is 6.70x versus 1.10x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LXRXLexicon Pharmaceuticals, Inc.6.70x -- $14.2M -$12.8M CRISCuris, Inc.1.10x -- $3.2M -$7.7M
-
Which has Higher Returns LXRX or LADX?
LadRx Corp. has a net margin of -90.04% compared to Lexicon Pharmaceuticals, Inc.'s net margin of --. Lexicon Pharmaceuticals, Inc.'s return on equity of -49.19% beat LadRx Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LXRXLexicon Pharmaceuticals, Inc.98.87% -$0.04 $185.1M LADXLadRx Corp.-- -$1.45 -- -
What do Analysts Say About LXRX or LADX?
Lexicon Pharmaceuticals, Inc. has a consensus price target of $2.92, signalling upside risk potential of 122.9%. On the other hand LadRx Corp. has an analysts' consensus of -- which suggests that it could grow by 434682.61%. Given that LadRx Corp. has higher upside potential than Lexicon Pharmaceuticals, Inc., analysts believe LadRx Corp. is more attractive than Lexicon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LXRXLexicon Pharmaceuticals, Inc.2 2 0 LADXLadRx Corp.0 0 0 -
Is LXRX or LADX More Risky?
Lexicon Pharmaceuticals, Inc. has a beta of 0.980, which suggesting that the stock is 1.993% less volatile than S&P 500. In comparison LadRx Corp. has a beta of 0.464, suggesting its less volatile than the S&P 500 by 53.583%.
-
Which is a Better Dividend Stock LXRX or LADX?
Lexicon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LadRx Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals, Inc. pays -- of its earnings as a dividend. LadRx Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LXRX or LADX?
Lexicon Pharmaceuticals, Inc. quarterly revenues are $14.2M, which are larger than LadRx Corp. quarterly revenues of --. Lexicon Pharmaceuticals, Inc.'s net income of -$12.8M is lower than LadRx Corp.'s net income of -$719.3K. Notably, Lexicon Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while LadRx Corp.'s PE ratio is 0.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals, Inc. is 6.70x versus -- for LadRx Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LXRXLexicon Pharmaceuticals, Inc.6.70x -- $14.2M -$12.8M LADXLadRx Corp.-- 0.84x -- -$719.3K
-
Which has Higher Returns LXRX or NVAX?
Novavax, Inc. has a net margin of -90.04% compared to Lexicon Pharmaceuticals, Inc.'s net margin of -287.29%. Lexicon Pharmaceuticals, Inc.'s return on equity of -49.19% beat Novavax, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LXRXLexicon Pharmaceuticals, Inc.98.87% -$0.04 $185.1M NVAXNovavax, Inc.71.9% -$1.25 $94.5M -
What do Analysts Say About LXRX or NVAX?
Lexicon Pharmaceuticals, Inc. has a consensus price target of $2.92, signalling upside risk potential of 122.9%. On the other hand Novavax, Inc. has an analysts' consensus of $12.89 which suggests that it could grow by 48.15%. Given that Lexicon Pharmaceuticals, Inc. has higher upside potential than Novavax, Inc., analysts believe Lexicon Pharmaceuticals, Inc. is more attractive than Novavax, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LXRXLexicon Pharmaceuticals, Inc.2 2 0 NVAXNovavax, Inc.5 1 1 -
Is LXRX or NVAX More Risky?
Lexicon Pharmaceuticals, Inc. has a beta of 0.980, which suggesting that the stock is 1.993% less volatile than S&P 500. In comparison Novavax, Inc. has a beta of 2.583, suggesting its more volatile than the S&P 500 by 158.251%.
-
Which is a Better Dividend Stock LXRX or NVAX?
Lexicon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Novavax, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LXRX or NVAX?
Lexicon Pharmaceuticals, Inc. quarterly revenues are $14.2M, which are smaller than Novavax, Inc. quarterly revenues of $70.4M. Lexicon Pharmaceuticals, Inc.'s net income of -$12.8M is higher than Novavax, Inc.'s net income of -$202.4M. Notably, Lexicon Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Novavax, Inc.'s PE ratio is 4.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals, Inc. is 6.70x versus 1.38x for Novavax, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LXRXLexicon Pharmaceuticals, Inc.6.70x -- $14.2M -$12.8M NVAXNovavax, Inc.1.38x 4.92x $70.4M -$202.4M
-
Which has Higher Returns LXRX or VMD?
Viemed Healthcare, Inc. has a net margin of -90.04% compared to Lexicon Pharmaceuticals, Inc.'s net margin of 5.01%. Lexicon Pharmaceuticals, Inc.'s return on equity of -49.19% beat Viemed Healthcare, Inc.'s return on equity of 10.37%.
Company Gross Margin Earnings Per Share Invested Capital LXRXLexicon Pharmaceuticals, Inc.98.87% -$0.04 $185.1M VMDViemed Healthcare, Inc.56.94% $0.09 $160.2M -
What do Analysts Say About LXRX or VMD?
Lexicon Pharmaceuticals, Inc. has a consensus price target of $2.92, signalling upside risk potential of 122.9%. On the other hand Viemed Healthcare, Inc. has an analysts' consensus of $13.00 which suggests that it could grow by 57.01%. Given that Lexicon Pharmaceuticals, Inc. has higher upside potential than Viemed Healthcare, Inc., analysts believe Lexicon Pharmaceuticals, Inc. is more attractive than Viemed Healthcare, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LXRXLexicon Pharmaceuticals, Inc.2 2 0 VMDViemed Healthcare, Inc.2 0 0 -
Is LXRX or VMD More Risky?
Lexicon Pharmaceuticals, Inc. has a beta of 0.980, which suggesting that the stock is 1.993% less volatile than S&P 500. In comparison Viemed Healthcare, Inc. has a beta of 1.273, suggesting its more volatile than the S&P 500 by 27.312%.
-
Which is a Better Dividend Stock LXRX or VMD?
Lexicon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viemed Healthcare, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Viemed Healthcare, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LXRX or VMD?
Lexicon Pharmaceuticals, Inc. quarterly revenues are $14.2M, which are smaller than Viemed Healthcare, Inc. quarterly revenues of $71.9M. Lexicon Pharmaceuticals, Inc.'s net income of -$12.8M is lower than Viemed Healthcare, Inc.'s net income of $3.6M. Notably, Lexicon Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Viemed Healthcare, Inc.'s PE ratio is 25.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals, Inc. is 6.70x versus 1.34x for Viemed Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LXRXLexicon Pharmaceuticals, Inc.6.70x -- $14.2M -$12.8M VMDViemed Healthcare, Inc.1.34x 25.05x $71.9M $3.6M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Is Sandisk The Next Big Memory Stock?
Computer memory manufacturer Sandisk (NASDAQ:SNDK) has quietly been one of…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
